TW200944225A - Cyclic compound and salt thereof - Google Patents
Cyclic compound and salt thereof Download PDFInfo
- Publication number
- TW200944225A TW200944225A TW098108269A TW98108269A TW200944225A TW 200944225 A TW200944225 A TW 200944225A TW 098108269 A TW098108269 A TW 098108269A TW 98108269 A TW98108269 A TW 98108269A TW 200944225 A TW200944225 A TW 200944225A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- salt
- culture
- strain
- medium
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 48
- 150000001923 cyclic compounds Chemical class 0.000 title abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 90
- 241000228209 Acremonium persicinum Species 0.000 claims abstract 2
- 239000000126 substance Substances 0.000 claims description 26
- 230000002538 fungal effect Effects 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 14
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 claims description 6
- 229910052742 iron Inorganic materials 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 5
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 4
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims description 3
- 229910052733 gallium Inorganic materials 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims 2
- 241000146061 Atriplex cinerea Species 0.000 claims 1
- 241000233866 Fungi Species 0.000 abstract description 11
- 230000000843 anti-fungal effect Effects 0.000 abstract description 8
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 8
- 229940124597 therapeutic agent Drugs 0.000 abstract description 6
- 208000031888 Mycoses Diseases 0.000 abstract description 5
- 230000000069 prophylactic effect Effects 0.000 abstract description 4
- 229940121375 antifungal agent Drugs 0.000 abstract description 3
- 239000003429 antifungal agent Substances 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 239000002609 medium Substances 0.000 description 28
- 239000000843 powder Substances 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- 229940126062 Compound A Drugs 0.000 description 12
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 244000005700 microbiome Species 0.000 description 9
- 239000013587 production medium Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- -1 carbitol Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 240000007472 Leucaena leucocephala Species 0.000 description 5
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 5
- 244000061456 Solanum tuberosum Species 0.000 description 5
- 235000002595 Solanum tuberosum Nutrition 0.000 description 5
- 240000008042 Zea mays Species 0.000 description 5
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 235000005822 corn Nutrition 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000012136 culture method Methods 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 241001553178 Arachis glabrata Species 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 108010068370 Glutens Proteins 0.000 description 3
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229910000373 gallium sulfate Inorganic materials 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N ornithyl group Chemical class N[C@@H](CCCN)C(=O)O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Inorganic materials [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 244000241257 Cucumis melo Species 0.000 description 2
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 241000682923 Gliomastix Species 0.000 description 2
- 229920002581 Glucomannan Polymers 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000274177 Juniperus sabina Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 239000003885 eye ointment Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940046240 glucomannan Drugs 0.000 description 2
- 235000021312 gluten Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 229910052707 ruthenium Inorganic materials 0.000 description 2
- 239000012748 slip agent Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- 241000256111 Aedes <genus> Species 0.000 description 1
- 240000007474 Aloe arborescens Species 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000356408 Candida cloacae Species 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000427940 Fusarium solani Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical group CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 244000251905 Pseudocydonia sinensis Species 0.000 description 1
- 241000223598 Scedosporium boydii Species 0.000 description 1
- 235000014459 Sorbus Nutrition 0.000 description 1
- 241001092391 Sorbus Species 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 241000223230 Trichosporon Species 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- HZVVJJIYJKGMFL-UHFFFAOYSA-N almasilate Chemical compound O.[Mg+2].[Al+3].[Al+3].O[Si](O)=O.O[Si](O)=O HZVVJJIYJKGMFL-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 238000011483 antifungal activity assay Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 229940055022 candida parapsilosis Drugs 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- CETPSERCERDGAM-UHFFFAOYSA-N ceric oxide Chemical compound O=[Ce]=O CETPSERCERDGAM-UHFFFAOYSA-N 0.000 description 1
- 229910000422 cerium(IV) oxide Inorganic materials 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000018842 conidium formation Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- MVLVMROFTAUDAG-UHFFFAOYSA-N ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC MVLVMROFTAUDAG-UHFFFAOYSA-N 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005242 forging Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 150000002258 gallium Chemical class 0.000 description 1
- SBDRYJMIQMDXRH-UHFFFAOYSA-N gallium;sulfuric acid Chemical compound [Ga].OS(O)(=O)=O SBDRYJMIQMDXRH-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 description 1
- 229940073769 methyl oleate Drugs 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- HSFQBFMEWSTNOW-UHFFFAOYSA-N sodium;carbanide Chemical group [CH3-].[Na+] HSFQBFMEWSTNOW-UHFFFAOYSA-N 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/145—Fungal isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
200944225 六、發明說明: 【發明所屬之技術領域】 本發明係一種醫藥組成物,其係關於適用爲治療真菌 病症,特別係深層真菌病症之醫藥組成物之有效成分的環 狀化合物。 【先前技術】 〇 深層真菌病症一般認爲係長時間對患者投予抗生素時 ,雖然去除了標的的病原菌,卻因可抵抗抗生素之真菌增 生而引發的病症(於此,存活之真菌異常地增殖的現象, 稱做細菌代換現象(microbial substitution)),亦即高 齡患者、術後患者、或正進行投予抗癌劑及免疫抑制劑之 患者,由於活體防禦功能被抑制變爲容易感染真菌,因該 真菌增殖而引發病症。 深層真菌病症的治療用藥有1)作用機轉爲阻礙真菌 〇 合成DNA之核酸鹼基系藥劑之氟胞嘧啶,及2)作用機轉 爲阻礙真菌合成細胞膜之多巨環內酯(Polyene macrolide )系藥劑之雙性黴素B、咪唑系藥劑之咪可納唑、以及三 哩系藥劑之氟康哩(Fluconazole)等抗真菌劑。 然而,雖已知如下所述之由3個鳥胺酸所構成之環狀 六胜肽之鐵色素(ferrichrome)(非專利文件1),但於 該文獻中並無鐵色素具有抗真菌活性之記載。 -5- 200944225 [化i]
非專利文件 1 : Journal of American Chemical Society, 102期,pp.4224-423 1, 1 980年 【發明內容】 [發明欲解決之課題] 本發明係提供一種醫藥組成物,其係適用爲治療真菌 病症,特別係深層真菌病症之醫藥組成物之有效成分的化 合物。 〇 [解決課題之手段] 本發明之發明者們,針對自然存在的微生物所產生之 具抗真菌作用之化合物進行專心檢討後,發現稱爲真菌桃 色枝頂孢MF - 347833株之菌株,可產生具優異抗真菌作 用之化合物。進而詳細檢討該菌株之培養液,成功地自該 菌株之培養液分離出具優異抗真菌作用之環狀化合物,遂 完成本發明。 亦即,本發明係關於式(I)之化合物或其鹽,以及 -6- 200944225 含有式(I)之化合物或其鹽、及賦形劑之醫藥組成物。 [化2]
另外’本發明係關於含有式(I)之化合物或其鹽之 治療真菌病症之醫藥組成物,即爲含有式(I)之化合物 或其鹽之真菌病症治療劑。 本發明係關於爲製造治療真菌病症之醫藥組成物之式 (Ο之化合物或其鹽之使用,以及包含對患者投予式(I )之化合物或其鹽之有效量之治療真菌病症之方法。 [發明的效果] 式(I)之化合物或其鹽可使用爲真菌病症,特別係 深層真菌病症等之預防及/或治療劑。 [實施發明之最佳方式] 以下詳細說明本發明。 本發明之化合物有時也會形成與鹼基之鹽。相關的鹽 200944225 具體而言可舉出與鈉、鉀、鎂鈣等無機鹼基、甲基胺、乙 基胺、乙醇胺、離胺酸、鳥胺酸等有機鹼基之鹽。另外, 鹽亦包含錯鹽及螯合化合物。形成相關鹽的金屬可舉出2 價或3價之金屬,例如可舉出鐵、鋁、鎵等。 以下,於本說明書中有時會將 式(I)之化合物之游離體記載爲化合物A、 式(I)之化合物之鋁鹽記載爲化合物B、 式(I)之化合物之鐵鹽記載爲化合物C、 式(I)之化合物之鎵鹽記載爲化合物D。 式(I)之化合物中能存在幾何異構物。本說明書中 ,式(I)之化合物有時僅以異構物的一個型態被記載, 但本發明亦包含其以外之異構物,及包含異構物經被分離 者,或該等之混合物。 另外式(I)之化合物中也有具有不對稱碳原子之情 況,以此爲基礎能存在光學異構物。本發明係包含式(I )之化合物之光學異構物經被分離者,或該等之混合物。 本發明進而包含以式(I)所示之化合物之製藥學上 被容許之前驅藥物。製藥學上被容許之前驅藥物係指於藉 由加溶媒分解或於生理學之條件下,具有能夠被變換爲圬 基等基之化合物。 本發明亦進而包含式(I)之化合物或其鹽之各種水 和物及溶媒和物,以及結晶多形之物質。另外,本發明亦 包含各種被放射性或非放射性同位素標誌後之化合物。 產生式(I)之化合物或其鹽之微生物的菌學性質如 -8- 200944225 下所示。 (1 )生產菌之由來 真菌頂孢黴屬MF- 347833株,係採集自馬來西亞之 新山州(Johor Bahru)的Endau Rompin國家公園內之腐落 葉植物所分離的。本菌株目前寄存於獨立行政法人產業技 術綜合硏究所專利生物寄存中心,寄存號碼爲FERM BP — 〇 10916 (寄存日爲2007年10月10日),並以寄存號碼BCRC 930 1 1 9寄存於食品工業發展硏究所。 (2)生產菌之型態學性質 型態上之特徵係觀察於馬鈴薯葡萄糖洋菜培養基上之 型態而判定。於馬鈴薯葡萄糖洋菜培養基(DifC0公司製 之2010 )上生長旺盛,於25 °C下2週後擴展至直徑爲39_ 41mm >亦發現形成分生孢子。菌落表面爲羊毛狀( ❹ floccose),菌落周圍則爲波浪狀(undulate)。雖自中央 部位向周圍部位產生數條放射狀的溝,但難以自表面確認 。菌落爲白色(white,1A1 ),但中央部位爲稍淺之黄白 色(yellowish white,4A2)。於菌落背面可確認自中央部 位向周圍部位產生呈現放射狀的溝。整體顏色爲淺米色( ivory,4A3 )’但菌落之中央部位爲淺棕色(mustard brown, 5E6 )。於30°C下2週後菌落之直徑爲約24mm, 未發現於5°C與3 7°C下有生長情形。 玉米萃取液洋菜培養基(Difco公司製之0386) 上生 200944225 長旺盛,於25°C下2週後擴展至直徑爲39-40mm。菌落表面 爲氈狀(felty )。菌落周圍則爲波浪狀(undulate )且菌 落中未產生溝。菌落爲白色(white, 1A1 )。菌落背面亦 爲白色(white,1A1)。於30°C下進行培養2週後菌落之直 徑爲約14mm。菌落表面未產生溝。未發現於5°C與37 °C下 有生長情形。 營養菌絲粗細爲1.8 _ 2.7 /zm,未觀察到厚膜孢子,分 生孢子柄無分枝,無色且單生於營養菌絲或細長之孢子束 。分生孢子柄表面存在許多小的疣狀突起,分生孢子柄的 根部有隔膜。分生孢子形成樣式爲瓶梗型,自分生孢子柄 根部至瓶梗前端長度爲33-40 #m。分生孢子爲無色的橢圓 形,大小爲3.7-4 ·5χ2·8-3.2/ζ m (平均爲4x3" m)。稍具 黏性,瓶梗前端形成孢子塊。以光學顯微鏡(4 00倍)可 見孢子的表面呈現平滑,但以電子顯微鏡(9000倍)觀察 則可確認呈劇烈凹凸形狀。 該等型態上之特徵暗示本菌屬於頂孢黴屬之可能性。 根據 Cephalosporium-artige Schimmelpilze ( Hyphomycetes )/Walter Gams ( 1971)比較檢討後,結果與 Gliomastix 節之桃色枝頂孢型態上之特徵十分一致。另外,檢索本菌 之28SrDNA與18SrDNA之相似性後,由於其包含於 Gliomastix節之桃色枝頂孢之群(clade ),形態上及基因 上均無矛盾。因此鑑定本菌爲桃色枝頂孢,並稱其爲桃色 枝頂孢MF - 347833株。 200944225 (3 )培養特性 培養特性係根據市售上培養基,以及以記載於文獻之 組成所調製之培養基而進行判定。分別購買Difco公司製 之2010馬鈴薯葡萄糖洋菜培養基、Difco公司製之0109沙 氏葡萄糖洋菜培養基、Difco公司製之0739EmerS〇n YpSs 洋菜培養基、Difco公司製之03 86玉米萃取液洋菜培養基 、Difco公司製之0552燕麥洋菜培養基。麥芽萃取洋菜培 Φ 養基、Czapek氏液狀洋菜培養基、MY20洋菜培養基之組 成係遵循 JCM 目錄(Nakase,T. 6th ed·, ρρ·617,Japan Collection of Microorganisms, the Institute of Physical and Chemical Research, Saitama, 1 9 9 5 ) o 觀察真菌MF- 3 47 833株自接種於各洋菜培養基開始 於25 °C下進行培養14天之情形。色調之記載係參照 Methuen Handbook of Colour (Kornerup, A. and J. H. Wanscher, 3rd e d. pp. 252, Methuen, London, 1 987) ° 有關 〇 生長溫度係於馬鈴薯葡萄糖洋菜培養基(Difco公司製之 2010 )上進行判定。 -11 - 200944225 [表i] 桃色枝頂孢MF - 347833株之培養特性 培養基 培養特性 生長:旺盛。直徑30-31mm 麥芽萃取洋菜 表面:圓形且周圍邊緣成波浪狀、羊毛狀、白色(1A1) 背面:淺黃色〜淺橘色(5A3) 生長:旺盛。直徑39-41mm 馬鈴薯葡萄糖洋菜 (Difco 2010) 表面:圓形且周圍邊緣成波浪狀、羊毛狀、 白色(1A1)〜黃白色(4A2) 背面:形成溝。淺米色(4A3)。 中央部位爲淺棕色(5E6) Czapek^'^^洋菜 生長:旺盛。直徑57-59mm 表面:圓形且周圍邊緣爲正圓。毵狀、 中央部位稍爲紅灰色(7B3)但整體爲白色(1A1) 背面:淺橘色(5A2) 生長:旺盛。直徑32-33mm 沙氏葡萄糖洋菜 表面:圓形且周圍邊緣成波浪狀。形成線條。 (Difco 0109) 羊毛狀、白色(1A1) 背面:形成溝。黃白色(4A2) 生長:旺盛。直徑36-38mm Emerson YpSs 洋菜 表面:圓形且周圍邊緣成波浪狀。耗狀、 (Difco 0739) 整體爲白色(1A1) 背面:淺橘色(5A2) 生長:旺盛。直徑39-40mm 玉米萃取液洋菜 表面:圓形且周圍邊緣成波浪狀。氈狀、 (Difco 0386) 整體爲白色(1A1) 背面:白色(1A1) 生長:旺盛。直徑34-35mm MY20洋菜 表面:圓形且周圍邊緣爲正圓。羊毛狀、 整體爲白色(1A1) 背面:淺黃色(4A4) 生長:旺盛。直徑5〇-51mm 燕麥洋菜 表面:圓形且周圍邊緣爲正圓。羊毛狀、 (Difco 0552) 中央部位爲淺黃色(4A2)但整體爲白色(1A1) 背面:淺黃色(4A4)
-12- 200944225 另外,本菌株有時會有人工的或天然的變異,於本發 明中所使用之真菌桃色枝頂孢MF - 3 4783 3株,除自自然 界所分離出之微生物之外,亦包含使其以紫外線、放射線 '化學藥劑等進行人工變異者以及該等之天然變異株。 (生產方法) 本發明之化合物係培養具有生產本發明化合物之能力 〇 之頂孢黴屬微生物而得。培養係以一般微生物之培養方法 爲準而進行。 培養基以選用含有真菌桃色枝頂孢MF - 347833株可 利用營養源之培養基爲佳,可使用合成培養基、半合成培 養基或天然培養基。培養基之組成做爲碳源者例如爲L-樹 膠醛醣、D-木醣、D-葡萄糖、D-果糖、蔗糖、肌醇、L-鼠 李糖、棉實糖、D-甘露糖醇、甘露糖、密二糖、乳糖、D-半乳糖、麥芽糖、海藻糖、水楊甘、葉黃素、幾丁質、澱 〇 粉、葡萄糖、葡聚糖、甘油、植物油等,氮源爲牛肉.萃取 物、消化蛋白質、筋粉、棉實粕、大豆粉、花生粉、魚粉 、玉米漿、乾燥酵母、酵母萃取液、氯化銨、硫酸銨、硝 酸銨、尿酸之外,使用有機、無機之氮來源。另外金屬鹽 可爲鈉、鉀、鎂、鈣、錫、鈷等之硫酸鹽、硝酸鹽、碳酸 鹽、磷酸鹽等可因應需要而添加。可進而因應需要添加蛋 胺酸、半胱胺酸、胱胺酸、硫代硫酸鹽、油酸甲酯、豬油 、二氧化矽油、界面活性劑等促進生成物質或消泡劑。 培養條件一般於好氧的條件下進行培養較有利,培養 -13- 200944225 溫度範圍於8.9〜31.2t,以於26.0〜27.6°C附近進行爲佳 。培養時間可因應培養基之組成、溫度條件適宜地加以設 定,但一般1〜30天左右,以2〜7天爲佳。 自培養物純化本發明化合物並進行分離之方法,可使 用一般自微生物之培養物純化具生理活性物質並進行分離 之方法。亦即,自培養物以適當的有機溶媒進行萃取,再 對該萃取物進行純化而分離出有效物質。亦即以抗真菌活 性爲指標,利用對於適當的溶劑之溶解性以及溶解度之差 別,藉由一般於製造生理活性物質所使用之方法而進行分 離、純化。該等方法可因應需要單獨使用,或以任意順序 進行組合、反覆進行。其他的純化方法可使用將原本之培 養物,或經離心分離、進行過濾後去除菌體之後,利用對 於適當的溶劑之溶解性以及溶解度之差別、自溶液析出速 度之差別、對各種吸附劑吸附親和性之差別、於2種液相 間分配之差別等方法。具體而言可舉出例如使培養液與適 當的載體接觸後使該化合物吸附,接著再藉由以適當的溶 媒進行溶出而純化該化合物之方法。可因應需要將該等方 法單獨使用,或以任意順序進行組合、反覆進行。 本發明之化合物,式(I)之化合物之鹽,係可於式 (I )之化合物中,將無機鹽(例如AlK(S〇4)2 · 12H2〇、 FeCl3 · 6H20 ' Ga2(S04)3 · ηΗ20等)使其於不會影響反應 之溶媒中,由室溫至加溫條件下進行反應而製造。溶媒無 特別限定,可舉出例如甲醇等含醇類之水溶液。反應溫度 以1 0 °C〜5 0 °C爲佳。 -14- 200944225 本發明之環狀化合物(I)或其鹽,可藉由於營養培 養基培養該物質之生產菌,再由蓄積該化合物之培養物中 依尋常用方法而得。於該化合物之製造方法中所使用之微 生物係屬於頂孢黴屬,可使用任一種具有產生該化合物之 能力之微生物。 含有1種或2種以上之式(I)之化合物或其鹽爲有效 成分之醫藥組成物,可使用於該領域中常使用之賦形劑, 〇 亦即藥劑用賦形劑及藥劑用載體等,根據常用方法而進行 調製。 投予可爲錠劑、九劑、膠囊劑、顆粒劑、散劑、液劑 等經口投予,或爲關節內、靜脈內、肌肉內等之注射劑、 坐劑、點眼劑、眼軟膏、經皮用液劑、軟膏劑、經皮用貼 付劑、經黏膜液劑、經黏膜貼付劑、吸入劑等非經口投予 之任一種型態。 爲進行經口投予之固體組成物可使用錠劑、散劑、顆 Ο 粒劑等。於該等固體組成物中,可將1種或2種以上之有效 成分’與至少一種的低活性賦形劑例如乳糖、甘露糖醇、 葡萄糖、羥基丙基纖維素、微結晶纖維素、澱粉、聚乙烯 批略烷酮、及/或鎂鋁矽酸鹽等進行混合。組成物可根據 常用方法亦可含有低活性添加劑例如硬酯酸鎂之滑澤劑, 及竣甲基澱粉鈉等崩解劑、安定劑、溶解輔助劑。錠劑或 九劑可根據需要以糖衣或胃溶性或腸溶性物質之薄膜進行 被膜。 爲進行經口投予之液體組成物含有於藥劑學上被容許 -15- 200944225 之乳濁劑、溶液劑、懸濁劑、糖漿劑或酏劑等,及含有一 般所使用之低活性稀釋劑例如純化水或乙醇。該液體組成 物除低活性稀釋劑之外亦可含有如可溶化劑、濕潤劑、懸 濁劑之輔助劑、甜味劑、風味劑、芳香劑、防腐劑。 爲進行非經口投予之注射劑含有無菌之水性或非水性 之溶液劑、懸濁劑或乳濁劑。水性溶劑可舉出包含例如注 射用蒸餾水或生理食鹽水溶液。非水性之溶劑可舉出例如 丙二醇、聚乙二醇或如橄欖油等之植物油、如乙醇之醇類 、或聚山梨醇酯80(藥典名)等。而該等組成物可進而含 有等張化劑、防腐劑、濕潤劑、乳化劑、分散劑、安定化 劑、或溶解輔助劑。再將該等物質通過可濾細菌過濾器進 行過濾、混合殺菌劑或輻射照射而進行無菌化。另外,可 將該等物質製造爲無菌之固體組成物,於使用前以無菌水 或無菌之注射用溶媒進行溶解或懸濁後再使用。 外用劑包含軟膏劑、硬膏劑、乳霜劑、凝膠劑、泡沫 劑、噴霧劑、乳液劑、點眼劑、眼軟膏等。含有一般所使 用之軟膏基劑、乳液基劑、水性或非水性之液劑、懸濁劑 、乳劑等。軟膏或乳液基劑可舉出例如聚乙二醇、丙二醇 、白色凡士林、蜜蟣、聚氧乙烯氫化蓖麻油、單硬酯酸乙 酯、硬酯酸醇、鯨蠟醇、聚桂醇、山梨醇倍半油酸酯等。 吸入劑及經鼻劑等經黏膜劑可使用固體、液體或半固 體狀者,可根據以往周知之方法進行製造。例如適當地於 周知之賦形劑中進而添加pH調整劑、防腐劑、界面活性劑 、滑澤劑、安定劑及增黏劑等亦可。投予可使用爲吸入或 -16- 200944225 吹送適當的裝置。例如可使用計量投予吸入裝置等周知之 裝置及噴霧器,將化合物單獨地或經處方之混合物的粉末 ’或於醫藥上被容許之載體組合後,成爲溶液或懸濁液而 進行投予。乾燥粉末吸入器等,可用於單次或數次投予用 者’可利用乾燥粉末或含乾燥粉末之膠囊。或者可使用適 當的推動劑,例如氟氯烴類、氫氟烷烴或二氧化碳等適合 氣體,而爲加壓氣霧噴劑等型態。 ❹ 一般經口投予時,1天的投予量約相當於每公斤體重 爲0.01〜100mg/kg’以0.1〜10mg/kg較爲適當,將其以 1次’或分做2次〜4次進行投予。進行靜脈內投予時,1天 的投予量約相當於每公斤體重爲0.01〜lOOmg / kg,1天1 次〜分做數次進行投予。投予量可考慮症狀、年齡、性別 等因應各個狀況而適當地加以決定。 式(I)之化合物或其鹽,可與被認爲前述之式(I) 之化合物或其鹽顯示有效性之疾病之各種治療劑或預防劑 Φ 進行倂用。該倂用可爲投時投予,或各別地連續地進行投 予,或可於所期望的時間間隔進行投予。投時進行投予之 製劑,可爲混合劑或可爲經各別製劑化者。 【實施方式】 [實施例] 以下以實施例爲基礎,將式(I)之化合物或其鹽之 製造方法更詳細地說明。且本發明並未限定於下述實施例 所記載之化合物。另外,式(I)之化合物或其鹽之製造 -17- 200944225 方法,亦非僅限定於以下所示之具體的實施例之製造法, 式(I)之化合物或其鹽可組合該等製造方法,或可根據 相關業者當然之方法進行製造。 另外,於實施例、製造例以及後述表中,有時會使用 以下之略碼。 [表2]
賴 Full name AlK(S〇4)2 . 12H20 硫酸鋁鉀12水合物 CHC13 氯仿 FeCl3 · 6H20 氯化鐵(瓜)6水合物 Ga2(S04)3 · ηΗ20 硫酸鎵(瓜冰合物 KC1 氯化鉀 KH2PO4 磷酸二氫鉀 MeCN 乙睛 MeOH 甲醇 MgS04 · 7H20 硫酸鎂7水合物 NaN03 硝_ (NH4)2S04 硫酸錶 TFA 三氟醋酸 HR ESI MS 高解析電灑式MS 實施例1 (化合物A之培養生產) 將基礎培養基1 (參照表3,30mL)分注至三角燒瓶( 尺寸:100mL)中,以高壓蒸氣滅菌器進行滅菌(121°C, 30分鐘)。於該基礎培養基1,以白金耳釣無菌方式進行 真菌MF - 347833株之斜面培養物(斜面培養物)之植菌 -18- 200944225 後,於25°C下進行4天以旋轉搖盪器之震盪培養( 220rpm )。其次,將生產培養基1(參照表4,lOOmL )分注至三 角燒瓶(尺寸:500mL)中,以高壓蒸氣滅菌器進行滅菌 (121 °C,30分鐘)。於該燒瓶以無菌方式植入基礎培養 物(2mL),於25 °C下進行7天以旋轉搖盪器之震盪培養 ( 220rpm)。培養係於以HPLC進行分析同時進行(分析 HPLC1,條件參照表5 )。 〇 [表3] 基礎培養基1 培養基成分 含有率(%) 玉米濺粉 2 甘油 1 蔗糖 1 藥劑培養基 1 筋粉 1 Tween 80 0.2 ❷ [表4] 生產培養基1 培養基成分 含有率(%) 葡萄糖 0.5 可溶性殿粉(NACALAI公司製) 1.5 酵母萃取物(和光純藥工業公司製) 0.5 KC1 0.02 MgS04· 7H20 0.02 KH2P〇4 0.1 NaN03 0.2 19- 200944225 [表5] 分析HPLC1之條件 管柱q Miehtvsil RP-18 GP 150-4.6(5μιη)關東化學公司製 移動相 MeCN :水=28 : 72(ν/ν)(含0·5%ΝΗ4Η2Ρ〇4) 流速 lmL/分 檢測波長 210nm 留滯時間 約4.2分 (化合物A之分離純化) 於以上述之培養方法所得之培養物(2.6L )中添加等 量之丙酮,攪拌1小時後進行過濾而得培養萃取物。於該 培養萃取液中加入2倍量之水,再使其通過Diaion SP 850 管柱(尺寸:400mL,三菱化學公司製),以混合溶媒{丙 酮:水= 30: 70(v/v) ,1.9L}進行溶出。 於該溶出液中加入水(2.1L),再使其通過Daisogel SP-120-ODS-B 管柱(尺寸:3 50mL,15/30"m,DAISO 公司製),以混合溶媒{MeCN :水=2 5 : 75 ( v/ v ), 340mL}進行溶出。 於該溶出液中加入水( 350mL),再使其通過OASIS HLB層析管柱(尺寸:6g,Waters公司製),以MeOH ( 150 mL)進行溶出。將該溶出液進行減壓濃縮,添加丙酮 後得沉源物。將該沉澱物進行乾燥後得黃色粉末(l〇〇mg )° 取該黃色粉末(15mg)溶解於少量之Me〇H,以製備 HPLC1進行純化(條件參照表6)。製備溶出時間爲約22 分之區段。於該取出區段之沖堤液中加入等量的水,再使 200944225 |S@〇ASIS HLB® 丰斤^主(R4:5〇〇mg) ’ 以水(5〇 mL )進行通液後,再以MeOH ( 50 mL )進行溶出。& 印將該 溶出液進行減壓濃縮,添加丙酮後得沉澱物。將該 Μ彳几锻物 進行乾燥後得化合物A( 13mg)之白色粉末。 [表6] 製備HPLC1之條件 管柱 Symmetry 7/i m C18管柱,19x300mm,Waters^wjg^'--- 移動相 MeCN :水=27 : 73(v/v)(含0.05%TFA)' 流速 7mL/分 ' — -----
(化合物A之物理化學上之性質) 以上述方法進行純化分離後之化合物A,顯示& 理化學上之性質。 [表7] 化合物Α物理化學上之性質 顏色及形狀 白色粉末 旋光度 Γα]〇25 -57 °(c 0.01, MeOH) 分子式 〇4〇Η62Νΐ〇〇13 HR ESI-MS Found 891.4592(M+H)+, Calcd 891.4576 IR(KBr) cm'1 3300, 2950, 1680, 1650,1640,1540, 1460,1420,1240,1210, 1160, 1040,970 h-NMR分析圖譜 如圖1所示 13C-NMR之分析圖譜 如圖2所示 〇 化合物A之化學構造根據物理化學性質決定如下述式 (Π)所述。針對構造胺基酸之立體結構,係適用改良 -21 - 200944225
Murphy法,並決定爲D-Phe,L-Leu,L-Asn。有關鳥胺酸 部分,與相似之天然物鐵色素(非專利文件1 )相比較, 由胺基酸分析得知3個胺基酸爲相同,推測爲L·鳥胺酸。 [化3]
(II) ❹ 實施例2 (化合物B及C之培養生產) 將基礎培養基2(參照表8)分注(30mL )至三角燒瓶 (尺寸:lOOmL)中,以高壓蒸氣滅菌器進行滅菌(121°C ,30分鐘)。於該培養基使用白金耳釣以無菌方式進行真 菌MF - 3 47 83 3株之斜面培養物(斜面培養物)之植菌後 ,於25°C下進行4天以旋轉搖盪器之震盪培養( 220rpm) 〇 其次,將相同組成之基礎培養基(160mL )分注至三 角燒瓶(尺寸:500mL )中,以高壓蒸氣滅菌器進行滅菌 (121 °C,30分鐘)。於該基礎培養機中以無菌方式植入 基礎培養物(3.2 mL ),於25 °C下進行3天以旋轉搖盪器 -22- 200944225 之震盪培養( 220rpm)。 其次,預先調製生產培養基2(參照表9),再將該生 產培養基2(2 0L)注入發酵槽(尺寸:30L),進行滅菌 (121 °C,30分鐘)後,以無菌方式植入基礎培養物(480 mL)。培養條件係通氣量爲20L/分,攪拌速度爲200rpm ,於25 °C下進行7天之培養。培養係於以HPLC進行分析同 時進行(分析HPLC2,條件參照表1 1 )。 〇 另外,使用生產培養基3取代生產培養基2以相同培養 條件可進行生產。 [表8]
基礎培養基2 培養基成分 含有率(%) 玉米源粉 2 甘油 1 蔗糖 1 藥劑培養基 1 筋粉 1 Tween 80 0.2 -23- 200944225 [表9] 生產培養基2 培養基成分 含有率 葡萄糖 - 可溶性锻粉(NACALAI公司製) 1.5 '^ 酵母萃取物(和光純藥工業公司製) Adekanol LG-109(ADEKA公司製) -----〜 0.05 二氧化砂KM-70(信越化學工業公司製) --- 0.05 KC1 0.02 MgS04 · 7H20 0.02 ^、 KH2P〇4 0.1 NaN03 0.2 、 [表 10] 生產培養基3 培養基成分 含有率 蔗糖 4 ^ 乾燥酵母潮日食品及健康關懷公司製) 1.5^^ (NH4)2S〇4 0.5 ''^' 碳酸鈣 0.5 ^〜 [表 11] 分析HPLC2之條件 管柱 移動相 流速 檢測波長 留滯時間
Mightysil RP-18 GP 15〇-4.6(5 ;m)關東化學ggpT MeCN :水=28 : 72(v/v脸0·5%ΝΗ4Η2Ρ〇4) lmL/分 _21〇mn^ 化合物B(約8.7分)$合物g(約1〇ϋ (化合物Β及C之分離純化) 200944225 於以上述之培養方法所得之培養物(生產培養基2: 90L )中添加等量之丙酮,攪拌1小時後進行過濾而得培養 萃取物。於該培養萃取液中加入等量之水,再使其通過 Diaion SP 850管柱(10L,三菱化學公司),以混合溶媒{ 丙酮:水= 40: 60 (v/v) ,40L}進行溶出。 於該溶出液中加入等量的水,再使其通過Daisogel 3?-120-008-8管柱(15/30//111,尺寸:21^,0人180公司 〇 製),以混合溶媒{MeCN :水=25 : 75 ( v/ V ) ,7L}進 行溶出。 於該溶出液中加入等量的水,使其再度通過Daisogel 8?-12 0-00 8 4管柱(尺寸:21〇 ,以混合溶媒{MeCN :水 =27.5 : 72.5 (含 0.05%TFA) ( v/v) }進行溶出。 於該溶出液中加入等量的水,使其再度通過Daisogel SP-120-ODS-B管柱(尺寸:180mL),以MeOH進行溶出 ,將該溶出液進行減壓濃縮。 參 將殘渣以少量的MeOH溶解,以製備HPLC2進行純化 (條件參照表1 2 )。 溶出時間爲約24〜25分之區段加入等量的水,使其通 過OAS IS HLB層析管柱(尺寸:6g,Waters公司製),以 水(100 mL )進行通液後,再以MeOH ( 1 〇〇 mL )進行溶 出。將該溶出液進行減壓濃縮,除去水後,藉由冷凍乾燥 ,得粉末狀之化合物C ( 130mg )。將該粉末以溶媒( MeOH、醋酸乙醋、正己院)進fj結晶化,得化合物c之橘 色結晶。 -25- 200944225 將對溶出時間爲約19〜21分之區段進行相同操作後所 得粉末’以CHCh溶解後,以矽凝膠管柱色層分析儀(球 狀6 0>1’中性,4〇-1〇〇以111,關東化學股份有限公司製, CHC13 : MeOH =10: 1)進行純化。將該溶出液進行減壓 濃縮,除去水後,藉由冷凍乾燥,得白色粉末狀之化合物 B ( 150mg )。將該粉末(109mg)以溶媒(MeOH、醋酸 乙酯、正己烷)進行結晶化,得無色結晶之化合物B( 9 0.1 m g )。 [表 12] 製備Η P L C 2之條件 管柱 Mightysil RP-18 GP管柱250x20mm Π).、關東化學公司製 移動相 MeCN :水=30 : 70(v/v)(含0.05%TFA) 流速 10mL/分 (化合物Β之物理化學上之性質) 以上述方法進行純化分離後之化合物Β’由於顯示以 下物理化學上之性質’推測爲化合物Α與鋁之比例爲1 : 1 之化合物。 200944225 [表 13] 化合物B物理化學上之性質 顏色及形狀 無色結晶 旋光度 Tab25 +210 °(c 0.01, MeOH) 分子式 C40H59AIN10O13 HR ESI-MS Found 951.4191(M+H)+, Calcd 915.4157 IR(KBr) cm*1 3300,2930, 1680,1650,1620,1520,1370, 1240, 1140, 990 融點 295〇C h-NMR分析圖譜 如圖3所示 13C-NMR之分析圖譜 如圖4所不 (化合物C之物理化學上之性質) 以上述方法進行純化分離後之化合物C,由於顯示以 下物理化學上之性質及自單結晶X繞射構造解析,決定爲 化合物A與鐵之比例爲1 : 1之化合物。 [表 14] 化合物C物理化學上之' 生質 顏色及形狀 橘色結晶 旋光度 Tab25 +256 °(c 0.01, MeOH) 分子式 C4〇H59FeN 1 〇〇i3 HRESI-MS Found 944.3693(M+H)+, Calcd 944.3691 單結晶X繞射構造解析 a= 13.850(1) A, b= 15.135(1) A, c=24.290(2) A, V=5091.6(6) A3 實施例3 (化合物D之製造) 將化合物A ( 4mg )溶解於MeOH ( 0.4mL )與水( -27- 200944225 0.4mL )之混合溶媒中,再加入Ga2 ( SO4 ) 3 · ηΗ20 ( 10mg)之水溶液(1.2mL),於2 5 °C下進行攪拌1 Μ、時。 於反應液中加入水(18 mL),使其通過OASIS HLB層析管 柱(Waters公司製),以水(6mL )進行通液後,再以 MeOH ( 4mL )進行溶出。將該溶出液進行減壓濃縮,得 白色粉末狀之化合物D(4mg)。 (化合物D之物理化學上之性質) 以上述方法所製造之化合物D,由於顯示以下物理化 學上之性質,推測爲化合物A與鎵之比例爲1 : 1之化合物 [表 15] 化合物D物理化學上之性質 分子式 C4〇H59GaNi〇〇i3 HRESI-MS Found 957.3597(M+H)+, Calcd 957.3597 t-NMR分析圖譜 如圖5所不 13C-NMR之分析圖譜 如圖6所τκ 實施例4 (抗真菌活性測定法) 以下述表所示之對於檢測菌之抗真菌活性,係使用微 量 '液體稀釋法(久米光,山崎敏和著,臨床與微生物,21 期5號,5 73-5 8 0頁,1 994年)進行測定。其結果,化合物 B對各種檢測菌之抗菌活性試驗之結果如下表所載。 -28- 200944225 [表 16] 化合物B之最小有效濃度(MEC) 檢測菌 MEC("g/mL) 克柔假絲酵母菌FP1979 0.31 光滑假絲酵母菌FP1944 0.31 高裏假絲酵母菌FP2086 0.31 近平滑假絲酵母菌FP1980 0.39 新型隱球菌FP1739 0.2 薰煙色麴菌FH305 0.31 土麴菌 SR0174 0.31 黑麹菌ATCC6275 0.78 黃麴菌ATCC9643 0.2 Trichosporon asashii FP2044 0.2 腐皮鐮孢FP1930 0.2 Pseudoallescheria boydii FP1987 0.2 米根黴FP1988 25 鬚髮癬菌FP2103 0.78 紅色毛癬菌FP596 1.25 碰孢菌AHU9258 0.1 根據上述試驗結果,確認式(I)之化合物或其鹽具 有抗真菌作用。因此,式(I)之化合物或其鹽可使用於 真菌病症,特別係深層真菌病症等例如副鼻腔炎真菌病症 之治療。 另外,例如鐵色素(自Sigma購入)對薰煙色麹菌 FP 1 3 05 之 MEC 爲 50// g/mL 以上。 實施例5 -29- 200944225 (細胞傷害性測定法) 對細胞之傷害性係於小鼠之T淋巴腫瘤細胞株之EL-4 細胞,添加入試驗藥劑之各種濃度,並於C02培養箱中於 3 7 °C下培養72小時後,使用細胞計數試劑組(和光純藥工 業公司製)測定細胞數,以計算IC5Q而進行判定。 其結果例如化合物B,於50 # g/ mL之濃度時並未顯 示對EL-4細胞之傷害性。 [產業上之利用可能性] 式(I)之化合物或其鹽可使用爲真菌病症,特別係 深層真菌病症等之預防及/或治療劑。 以上本發明沿用特定的方式進行說明,但相關業者當 然的改變及改良亦包含於本發明之範圍內。 【圖式簡單說明】 [圖1]圖1係化合物A之1H-NMR之分析圖譜。(測定溶 媒爲 d6-DMSO ) [圖2]圖2係化合物A之13C-NMR之分析圖譜。(測定溶 媒爲 d6-DMSO ) [圖3]圖3係化合物B之1H_NMR之分析圖譜。(測定溶 媒爲 d6-DMSO ) [圖4]圖4係化合物B之13C-NMR之分析圖譜。(測定溶 媒爲 d6-DMSO) [圖5]圖5係化合物D之1 H-NMR之分析圖譜。(測定溶 200944225 媒爲 d6-DMSO ) [圖6]圖6係化合物D之13 C-NMR之分析圖譜。(測定溶 媒爲 d6-DMSO )
-31 -
Claims (1)
- 200944225 七、申請專利範圍: I—種化合物或其鹽,其係如式(I)所示, [化1]2.如申請專利範圍第1項之化合物或其鹽,其中申請 專利範圍第1項中之化合物之鹽係與鋁或鐵之鹽。 3·如申請專利範圍第1項之化合物或其鹽,其中申請 專利範圍第1項中之化合物之鹽係與鋁之鹽。 4. 一種菌株,其寄存號碼係BCRC 93 0 1 1 9之桃色枝頂 孢 MF - 347833 株(Acremonium persicinum MF - 347833 株 )° 5. 如申請專利範圍第1項之化合物或其鹽,其係培養. 如申請專利範圍第4項之菌株,再藉由對該培養液進行萃 取·純化而可得。 6. —種如申請專利範圍第1項之化合物或其鹽之製造 方法,其係包含培養屬於真菌枝頂孢屬之菌株’再自該培 養液中分離出式(I)之化合物。 7. 如申請專利範圍第6項之製造方法’其中屬於真菌 枝頂孢屬之菌株係申請專利範圍第4項之菌株。 200944225 8. 如申請專利範圍第1項之化合物或其鹽,其中申請 專利範圍第1項中之化合物之鹽係與鎵之鹽。 9. 一種醫藥組成物,其特徵爲含有如申請專利範圍第 1項之化合物或其鹽、以及於製藥學上被容許之賦形劑。 10·—種使用於預防或治療真菌病症之醫藥組成物, 其特徵爲含有如申請專利範圍第1項之化合物或其鹽。 11. 一種如申請專利範圍第1項之化合物或其鹽之使用 ❹,其 特徵爲使用於預防或治療真菌病症之醫藥組成物之製 造者。 12·—種如申請專利範圍第1項之化合物或其鹽之使用 ,其特徵爲使用於預防或治療真菌病症者。 13.—種預防或治療真菌病症之方法,其特徵爲包含 對患者投予申請專利範圍第1項之化合物或其鹽之有%^ 〇 ❹ -33-
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008065202 | 2008-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200944225A true TW200944225A (en) | 2009-11-01 |
Family
ID=41065322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW098108269A TW200944225A (en) | 2008-03-14 | 2009-03-13 | Cyclic compound and salt thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8598115B2 (zh) |
| EP (1) | EP2261238B1 (zh) |
| JP (1) | JP5387567B2 (zh) |
| KR (1) | KR101558632B1 (zh) |
| CN (1) | CN101970462B (zh) |
| AU (1) | AU2009224302C1 (zh) |
| BR (1) | BRPI0909142B8 (zh) |
| CA (1) | CA2718395C (zh) |
| ES (1) | ES2464723T3 (zh) |
| IL (1) | IL208058A (zh) |
| MX (1) | MX2010009953A (zh) |
| PL (1) | PL2261238T3 (zh) |
| PT (1) | PT2261238E (zh) |
| RU (1) | RU2482130C2 (zh) |
| TW (1) | TW200944225A (zh) |
| WO (1) | WO2009113661A1 (zh) |
| ZA (1) | ZA201006445B (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2408190T3 (es) * | 2008-03-14 | 2013-06-18 | Astellas Pharma Inc. | Microorganismo productor de un compuesto cíclico |
| CN102746996B (zh) * | 2012-07-26 | 2013-06-12 | 北方民族大学 | 一株产苦参碱的枝顶孢属真菌及其应用和其发酵液的应用 |
| US10513861B2 (en) * | 2016-10-19 | 2019-12-24 | Tait Towers Manufacturing, LLC | Modular auditorium |
| WO2022215745A1 (ja) * | 2021-04-08 | 2022-10-13 | 国立研究開発法人理化学研究所 | 新規シデロフォア型抗真菌剤(化合物)の物質及びその用途 |
| WO2025114603A1 (en) | 2023-11-30 | 2025-06-05 | Basilea Pharmaceutica International Ag, Allschwil | Pharmaceutical combinations for use in the treatment of fungal infections |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8925593D0 (en) * | 1989-11-13 | 1990-01-04 | Fujisawa Pharmaceutical Co | Fr901379 substance and preparation thereof |
| WO1992017496A1 (en) * | 1991-03-18 | 1992-10-15 | Panlabs, Incorporated | Isolation and sequence of the acetyl coa:deacetylcephalosporin acetyltransferase gene |
| DE69317539T2 (de) | 1992-03-31 | 1998-07-23 | Japan Tobacco Inc | Herbizid, das ein zyklisches hexapeptid als aktiven inhaltsstoff enthält |
| US5919691A (en) | 1994-10-06 | 1999-07-06 | Novo Nordisk A/S | Enzyme and enzyme preparation with endoglucanase activity |
| JP3920430B2 (ja) | 1996-12-18 | 2007-05-30 | 協和醗酵工業株式会社 | Ucs1025化合物 |
| DE69706950T2 (de) | 1996-12-18 | 2002-04-25 | Kyowa Hakko Kogyo Co., Ltd. | Furoindolizine |
| AUPP172898A0 (en) * | 1998-02-09 | 1998-03-05 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| EP1053247A1 (en) | 1998-02-09 | 2000-11-22 | Fujisawa Pharmaceutical Co., Ltd. | Antifungal cyclohexapeptides |
| US20060004185A1 (en) * | 2004-07-01 | 2006-01-05 | Leese Richard A | Peptide antibiotics and peptide intermediates for their prepartion |
| JP4836629B2 (ja) | 2006-03-30 | 2011-12-14 | 学校法人北里研究所 | 抗菌活性または抗腫瘍活性を有する化合物およびその製造方法 |
| JP5388405B2 (ja) | 2006-03-31 | 2014-01-15 | 旭化成ケミカルズ株式会社 | ポリイソシアネート組成物、及び二液型ポリウレタン組成物 |
| WO2008020260A2 (en) | 2006-08-16 | 2008-02-21 | R-Ko-N Kft. | Use of siderophores in prevention of vascular diseases, production of siderophores and qualifying siderophore containing meat-products |
| ES2408190T3 (es) * | 2008-03-14 | 2013-06-18 | Astellas Pharma Inc. | Microorganismo productor de un compuesto cíclico |
-
2009
- 2009-03-13 CA CA2718395A patent/CA2718395C/en active Active
- 2009-03-13 BR BRPI0909142A patent/BRPI0909142B8/pt active IP Right Grant
- 2009-03-13 PT PT97206866T patent/PT2261238E/pt unknown
- 2009-03-13 CN CN2009801088958A patent/CN101970462B/zh active Active
- 2009-03-13 EP EP09720686.6A patent/EP2261238B1/en active Active
- 2009-03-13 RU RU2010141977/04A patent/RU2482130C2/ru active
- 2009-03-13 ES ES09720686.6T patent/ES2464723T3/es active Active
- 2009-03-13 PL PL09720686T patent/PL2261238T3/pl unknown
- 2009-03-13 TW TW098108269A patent/TW200944225A/zh unknown
- 2009-03-13 WO PCT/JP2009/054876 patent/WO2009113661A1/ja not_active Ceased
- 2009-03-13 MX MX2010009953A patent/MX2010009953A/es active IP Right Grant
- 2009-03-13 US US12/922,337 patent/US8598115B2/en active Active
- 2009-03-13 JP JP2010502895A patent/JP5387567B2/ja active Active
- 2009-03-13 AU AU2009224302A patent/AU2009224302C1/en not_active Ceased
- 2009-03-13 KR KR1020107022316A patent/KR101558632B1/ko active Active
-
2010
- 2010-09-07 IL IL208058A patent/IL208058A/en not_active IP Right Cessation
- 2010-09-08 ZA ZA2010/06445A patent/ZA201006445B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009113661A1 (ja) | 2009-09-17 |
| AU2009224302C1 (en) | 2014-01-30 |
| MX2010009953A (es) | 2010-09-30 |
| ES2464723T3 (es) | 2014-06-03 |
| CA2718395A1 (en) | 2009-09-17 |
| AU2009224302B2 (en) | 2013-07-04 |
| KR20110005691A (ko) | 2011-01-18 |
| RU2010141977A (ru) | 2012-04-20 |
| EP2261238A1 (en) | 2010-12-15 |
| EP2261238B1 (en) | 2014-05-07 |
| PT2261238E (pt) | 2014-06-09 |
| IL208058A0 (en) | 2010-12-30 |
| US8598115B2 (en) | 2013-12-03 |
| RU2482130C2 (ru) | 2013-05-20 |
| BRPI0909142B1 (pt) | 2019-11-12 |
| EP2261238A4 (en) | 2012-04-25 |
| CA2718395C (en) | 2016-07-05 |
| BRPI0909142B8 (pt) | 2021-05-25 |
| US20110015121A1 (en) | 2011-01-20 |
| CN101970462A (zh) | 2011-02-09 |
| CN101970462B (zh) | 2013-06-19 |
| BRPI0909142A2 (pt) | 2015-08-04 |
| ZA201006445B (en) | 2011-12-28 |
| JPWO2009113661A1 (ja) | 2011-07-21 |
| KR101558632B1 (ko) | 2015-10-07 |
| PL2261238T3 (pl) | 2014-10-31 |
| AU2009224302A1 (en) | 2009-09-17 |
| JP5387567B2 (ja) | 2014-01-15 |
| IL208058A (en) | 2013-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5863648B2 (ja) | 新規環状ペプチド化合物とその製造方法及び感染症治療薬、抗生物質含有画分、その抗生物質及びその抗生物質の製造方法並びに抗生物質産生微生物及びそれが産生した抗生物質 | |
| JPH03184921A (ja) | 新規ポリペプチド化合物およびその製造法 | |
| JP5275337B2 (ja) | 環状化合物を生産する微生物 | |
| TW200944225A (en) | Cyclic compound and salt thereof | |
| US20120059038A1 (en) | Polyketide compound | |
| EP0584360A1 (en) | Wf11243 substance | |
| WO1997001575A1 (en) | Substance wf16616, process for production thereof, and use thereof | |
| JP2661367B2 (ja) | Wf11243物質 | |
| JPH09511902A (ja) | Wf15604物質 | |
| JPWO1992019648A1 (ja) | Wf11243物質 | |
| HU211527A9 (hu) | Az átmeneti oltalom az 1. és 6-8. igénypontokra vonatkozik | |
| JP2003520804A (ja) | 新規な環状化合物 | |
| JPH05112599A (ja) | Wf11243物質、その製法及び生物学的利用 | |
| JP2004275060A (ja) | ヒアルロン酸−cd44結合阻害剤及びその製造法 |